CY1119399T1 - Aντι-dkk-1 αντισωματα - Google Patents
Aντι-dkk-1 αντισωματαInfo
- Publication number
- CY1119399T1 CY1119399T1 CY20171101022T CY171101022T CY1119399T1 CY 1119399 T1 CY1119399 T1 CY 1119399T1 CY 20171101022 T CY20171101022 T CY 20171101022T CY 171101022 T CY171101022 T CY 171101022T CY 1119399 T1 CY1119399 T1 CY 1119399T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dkk
- antibodies
- human
- antigen
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16841109P | 2009-04-10 | 2009-04-10 | |
| PCT/US2010/030039 WO2010117980A1 (en) | 2009-04-10 | 2010-04-06 | Dkk-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119399T1 true CY1119399T1 (el) | 2018-02-14 |
Family
ID=42199718
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101022T CY1119399T1 (el) | 2009-04-10 | 2017-09-29 | Aντι-dkk-1 αντισωματα |
| CY20191100531T CY1121637T1 (el) | 2009-04-10 | 2019-05-17 | Αντι-dkk-1 αντισωματα |
| CY20211100700T CY1124412T1 (el) | 2009-04-10 | 2021-08-06 | Aνti-dkk-1 αντισωματα |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100531T CY1121637T1 (el) | 2009-04-10 | 2019-05-17 | Αντι-dkk-1 αντισωματα |
| CY20211100700T CY1124412T1 (el) | 2009-04-10 | 2021-08-06 | Aνti-dkk-1 αντισωματα |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8148498B2 (https=) |
| EP (3) | EP2417158B9 (https=) |
| JP (1) | JP5759977B2 (https=) |
| KR (3) | KR20110124364A (https=) |
| CN (1) | CN102388065B (https=) |
| AR (1) | AR075989A1 (https=) |
| AU (1) | AU2010234611B2 (https=) |
| BR (1) | BRPI1014157B1 (https=) |
| CA (1) | CA2758252C (https=) |
| CY (3) | CY1119399T1 (https=) |
| DK (3) | DK2930184T3 (https=) |
| EA (1) | EA021401B1 (https=) |
| ES (3) | ES2887176T3 (https=) |
| HR (3) | HRP20171400T1 (https=) |
| HU (3) | HUE055376T2 (https=) |
| IL (1) | IL214845A (https=) |
| LT (3) | LT2930184T (https=) |
| ME (2) | ME02798B (https=) |
| MX (1) | MX2011010707A (https=) |
| NZ (1) | NZ595011A (https=) |
| PL (3) | PL2930184T3 (https=) |
| PT (3) | PT2930184T (https=) |
| RS (3) | RS58612B1 (https=) |
| SG (1) | SG175244A1 (https=) |
| SI (3) | SI2930184T1 (https=) |
| TR (1) | TR201907261T4 (https=) |
| TW (1) | TWI546079B (https=) |
| UA (1) | UA103916C2 (https=) |
| WO (1) | WO2010117980A1 (https=) |
| ZA (1) | ZA201107256B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120475A1 (es) | 2009-05-12 | 2012-05-05 | Pfizer | Anticuerpos especificos para dkk-1 |
| CN111961134B (zh) | 2012-12-10 | 2024-04-05 | 比奥根Ma公司 | 抗血液树突细胞抗原2抗体及其用途 |
| AU2016263030A1 (en) * | 2015-05-18 | 2017-10-12 | Eli Lilly And Company | Anti-Dkk-1-anti-RANKL bispecific antibody compounds |
| CA2996059A1 (en) * | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| KR102701695B1 (ko) | 2016-10-26 | 2024-08-30 | 리프 테라퓨틱스 인코포레이티드 | 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| MX2020013172A (es) | 2018-06-08 | 2021-03-29 | Alector Llc | Anticuerpos anti-siglec-7 y sus metodos de uso. |
| AU2019301160A1 (en) * | 2018-07-11 | 2021-02-25 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4 |
| CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
| BR112022004851A2 (pt) * | 2019-09-19 | 2022-08-23 | Leap Therapeutics Inc | Uso de inibidores de dkk-1 para tratar câncer |
| EP4061419A1 (en) | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| KR102494042B1 (ko) | 2020-11-20 | 2023-02-07 | 주식회사 하울바이오 | 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도 |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
| IL304927A (en) * | 2021-02-05 | 2023-10-01 | Omeros Corp | A biomarker for assessing the risk of developing acute COVID-19 and post-acute COVID-19 |
| WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
| EP4471056A4 (en) * | 2022-01-28 | 2026-02-18 | Shanghai Junshi Biosciences Co Ltd | Anti-DKK1 antibodies, pharmaceutical composition and associated uses |
| KR20250057775A (ko) | 2022-07-12 | 2025-04-29 | 리프 테라퓨틱스 인코포레이티드 | 조합 요법 |
| CN116589590B (zh) * | 2023-03-21 | 2024-03-26 | 浙江大学 | 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU7137398A (en) | 1997-04-16 | 1998-11-11 | Millennium Pharmaceuticals, Inc. | Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US7446181B2 (en) * | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| JP3868740B2 (ja) | 1998-03-10 | 2007-01-17 | ジェネンテック・インコーポレーテッド | 新規なポリペプチド及びそれをコードする核酸 |
| CA2399776A1 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7736654B2 (en) | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| IL158750A0 (en) | 2001-05-17 | 2004-05-12 | Genome Therapeutics Corp | Reagents and methods for modulating dkk-mediated interactions |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| US7308364B2 (en) * | 2001-11-07 | 2007-12-11 | The University Of Arkansas For Medical Sciences | Diagnosis of multiple myeloma on gene expression profiling |
| JP2005512557A (ja) | 2001-11-07 | 2005-05-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー | 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定 |
| US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| EP1636388A2 (en) | 2003-06-06 | 2006-03-22 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| AR060017A1 (es) * | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| CN101641373B (zh) * | 2007-02-08 | 2015-02-11 | 默沙东公司 | Dkk-1的特异性抗体 |
| CN102421798A (zh) * | 2009-05-07 | 2012-04-18 | 诺瓦提斯公司 | 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法 |
-
2010
- 2010-03-29 AR ARP100101019A patent/AR075989A1/es active IP Right Grant
- 2010-04-02 TW TW099110438A patent/TWI546079B/zh active
- 2010-04-06 SI SI201031877T patent/SI2930184T1/sl unknown
- 2010-04-06 US US12/754,637 patent/US8148498B2/en active Active
- 2010-04-06 ME MEP-2017-212A patent/ME02798B/me unknown
- 2010-04-06 SI SI201031526T patent/SI2417158T1/sl unknown
- 2010-04-06 NZ NZ595011A patent/NZ595011A/xx unknown
- 2010-04-06 SI SI201032080T patent/SI3514173T1/sl unknown
- 2010-04-06 HR HRP20171400TT patent/HRP20171400T1/hr unknown
- 2010-04-06 KR KR1020117023571A patent/KR20110124364A/ko not_active Ceased
- 2010-04-06 BR BRPI1014157-0A patent/BRPI1014157B1/pt active IP Right Grant
- 2010-04-06 PL PL15159780T patent/PL2930184T3/pl unknown
- 2010-04-06 JP JP2012504760A patent/JP5759977B2/ja active Active
- 2010-04-06 PT PT15159780T patent/PT2930184T/pt unknown
- 2010-04-06 EA EA201171237A patent/EA021401B1/ru not_active IP Right Cessation
- 2010-04-06 MX MX2011010707A patent/MX2011010707A/es active IP Right Grant
- 2010-04-06 EP EP10712681.5A patent/EP2417158B9/en active Active
- 2010-04-06 LT LTEP15159780.4T patent/LT2930184T/lt unknown
- 2010-04-06 ES ES19156509T patent/ES2887176T3/es active Active
- 2010-04-06 DK DK15159780.4T patent/DK2930184T3/da active
- 2010-04-06 DK DK10712681.5T patent/DK2417158T4/da active
- 2010-04-06 AU AU2010234611A patent/AU2010234611B2/en active Active
- 2010-04-06 PL PL10712681T patent/PL2417158T3/pl unknown
- 2010-04-06 WO PCT/US2010/030039 patent/WO2010117980A1/en not_active Ceased
- 2010-04-06 HU HUE19156509A patent/HUE055376T2/hu unknown
- 2010-04-06 LT LTEP10712681.5T patent/LT2417158T/lt unknown
- 2010-04-06 HU HUE10712681A patent/HUE034625T2/en unknown
- 2010-04-06 PT PT107126815T patent/PT2417158T/pt unknown
- 2010-04-06 HU HUE15159780A patent/HUE043904T2/hu unknown
- 2010-04-06 UA UAA201111272A patent/UA103916C2/ru unknown
- 2010-04-06 PT PT191565092T patent/PT3514173T/pt unknown
- 2010-04-06 KR KR1020147005305A patent/KR101461362B1/ko active Active
- 2010-04-06 LT LTEP19156509.2T patent/LT3514173T/lt unknown
- 2010-04-06 EP EP19156509.2A patent/EP3514173B8/en active Active
- 2010-04-06 RS RS20190470A patent/RS58612B1/sr unknown
- 2010-04-06 ES ES15159780T patent/ES2728911T3/es active Active
- 2010-04-06 CA CA2758252A patent/CA2758252C/en active Active
- 2010-04-06 PL PL19156509T patent/PL3514173T3/pl unknown
- 2010-04-06 SG SG2011075579A patent/SG175244A1/en unknown
- 2010-04-06 CN CN201080015994.4A patent/CN102388065B/zh active Active
- 2010-04-06 RS RS20210998A patent/RS62214B1/sr unknown
- 2010-04-06 TR TR2019/07261T patent/TR201907261T4/tr unknown
- 2010-04-06 ME MEP-2019-98A patent/ME03378B/me unknown
- 2010-04-06 KR KR1020147018130A patent/KR20140090273A/ko not_active Ceased
- 2010-04-06 RS RS20170959A patent/RS56505B1/sr unknown
- 2010-04-06 EP EP15159780.4A patent/EP2930184B1/en active Active
- 2010-04-06 ES ES10712681.5T patent/ES2644244T3/es active Active
- 2010-04-06 DK DK19156509.2T patent/DK3514173T3/da active
-
2011
- 2011-08-25 IL IL214845A patent/IL214845A/en active IP Right Grant
- 2011-10-04 ZA ZA2011/07256A patent/ZA201107256B/en unknown
-
2017
- 2017-09-29 CY CY20171101022T patent/CY1119399T1/el unknown
-
2019
- 2019-04-03 HR HRP20190643TT patent/HRP20190643T1/hr unknown
- 2019-05-17 CY CY20191100531T patent/CY1121637T1/el unknown
-
2021
- 2021-08-06 CY CY20211100700T patent/CY1124412T1/el unknown
- 2021-08-20 HR HRP20211343TT patent/HRP20211343T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119399T1 (el) | Aντι-dkk-1 αντισωματα | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| CY1125977T1 (el) | Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης | |
| CY1123883T1 (el) | Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1125267T1 (el) | Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn | |
| CY1124292T1 (el) | Συνθεσεις για τροποποιηση της εκφρασης tau | |
| CY1122593T1 (el) | Αντισωματα εναντι-cd40 και χρησεις αυτων | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| CY1121167T1 (el) | Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων | |
| CY1121299T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
| CY1120412T1 (el) | Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31 | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1119070T1 (el) | Διαμορφωση της εκφρασης τρανσθυρετινης | |
| CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
| EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| CY1116886T1 (el) | C-met αντισωματα | |
| CY1118244T1 (el) | Αντισωματα κατα της il-25 | |
| CY1118761T1 (el) | Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3) | |
| MX2014015830A (es) | Anticuerpos lsr y usos de los mismos para el tratamiento de cancer. | |
| BR112014029883A2 (pt) | anticorpo totalmente humano, fragmento fab de anticorpo, anticorpo humano de cadeia única e método para tratar um amplo espectro de cânceres. |